Scilex Holding Company reports developments tied to its non-opioid pain management business, pharmaceutical assets and related healthcare investments. The company acquires, develops and commercializes products for acute and chronic pain, including ZTlido for postherpetic neuralgia, ELYXYB for acute migraine treatment in adults and Gloperba for prophylaxis of gout flares in adults.
Recurring Scilex news also includes material agreements, capital-structure actions, shareholder distributions involving Dream Bowl tokens, intellectual property and litigation counsel matters, strategic investments, clinical or regulatory disclosures, governance updates and operating and financial results.
Scilex Holding Company is taking steps to combat manipulative and naked short selling practices in its common stock. The company provided information to its stockholders regarding short selling activities. Scilex believes there are approximately 10 million shares being sold short and more than 10 million Dividend Shares sold as 'naked short' positions. It is determined to protect shareholder value and rights by addressing these practices.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.